Annexon Inc

ANNX

Healthcare|Biotechnology|USA

$5.79

-0.14 (-2.36%)

Tangible Book

$1.26

Earnings Power

$0.88

About

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Stock Price

+107.0%(1Y)

Pipeline Summary

15 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 12Terminated: 1Active: 1Recruiting: 1

Active Trials (2)

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

Phase 3Active

Enrollment: 659 participants

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

NCT07020819Guillain-Barre Syndrome

Phase 3Recruiting

Enrollment: 30 participants

BioScore

3.6/10

Cautious

Ownership

Recent Insider Trades

Satter Muneer ABUY

2026-05-28613,497 shares @ $5.41

Carson William H.BUY

2026-05-118,000 shares @ $5.78

Carson William H.BUY

2026-04-108,000 shares @ $6.2

Carson William H.BUY

2026-03-108,000 shares @ $5.67

Dananberg JamieSELL

2026-03-025,820 shares @ $5.43

Data last updated: Jul 13, 2026, 12:48 PM